This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Toth, K. Articles by Wold, W. S. M. Search for Related Content PubMed PubMed Citation Articles by Toth, K. Articles by Wold, W. S. M.

An Oncolytic Adenovirus Vector Combining Enhanced Cell-to-Cell Spreading, Mediated by the ADP Cytolytic Protein, with Selective Replication in Cancer Cells with Deregulated Wnt Signaling

¹ Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, Missouri; ² ML Laboratories PLC, Stephenson Building, Keele University Science Park, Keele, United Kingdom; and ³ VirRx, Inc., St. Louis, Missouri

We have constructed a novel oncolytic adenovirus (Ad) vector named VRX-009 that combines enhanced cell spread with tumor-specific replication. Enhanced spread, which could significantly increase antitumor efficacy, is mediated by overexpression of the Ad cytolytic protein named ADP (also known as E3–11.6K). Replication of VRX-009 is restricted to cells with a deregulated wnt signal transduction pathway by replacement of the wild-type Ad E4 promoter with a synthetic promoter consisting of five consensus binding sites for the T-cell factor transcription factor. Tumor-selective replication is indicated by several lines of evidence. VRX-009 expresses E4ORF3, a representative Ad E4 protein, only in colon cancer cell lines. Furthermore, VRX-009 replicates preferentially in colon cancer cell lines as evidenced by virus productivity 2 orders of magnitude higher in SW480 colon cancer cells than in A549 lung cancer cells. Replication in primary human bronchial epithelial cells and human umbilical vein endothelial cells was also significantly lower than in SW480 cells. When tested in human tumor xenografts in nude mice, VRX-009 effectively suppressed the growth of SW480 colon tumors but not of A549 lung tumors. VRX-009 may provide greater level of antitumor efficacy than standard oncolytic Ad vectors in tumors in which a defect in wnt signaling increases the level of nuclear ß-catenin.

This article has been cited by other articles:

				F. Dallaire, P. Blanchette, P. Groitl, T. Dobner, and P. E. Branton Identification of Integrin {alpha}3 as a New Substrate of the Adenovirus E4orf6/E1B 55-Kilodalton E3 Ubiquitin Ligase Complex J. Virol., June 1, 2009; 83(11): 5329 - 5338. [Abstract] [Full Text] [PDF]

				G. Glockzin, K. Mantwill, K. Jurchott, A. Bernshausen, A. Ladhoff, H.-D. Royer, B. Gansbacher, and P. S. Holm Characterization of the Recombinant Adenovirus Vector AdYB-1: Implications for Oncolytic Vector Development. J. Virol., April 1, 2006; 80(8): 3904 - 3911. [Abstract] [Full Text] [PDF]

				T. Subramanian, S. Vijayalingam, and G. Chinnadurai Genetic Identification of Adenovirus Type 5 Genes That Influence Viral Spread J. Virol., February 15, 2006; 80(4): 2000 - 2012. [Abstract] [Full Text] [PDF]

				M. A. Thomas, J. F. Spencer, M. C. La Regina, D. Dhar, A. E. Tollefson, K. Toth, and W. S.M. Wold Syrian Hamster as a Permissive Immunocompetent Animal Model for the Study of Oncolytic Adenovirus Vectors Cancer Res., February 1, 2006; 66(3): 1270 - 1276. [Abstract] [Full Text] [PDF]

				M. A. Pierce, A. Svetlanov, M. S. Horwitz, and D. V. Serreze Adenovirus Early Region 3 Transgenes Expressed in {beta} Cells Prevent Autoimmune Diabetes in Nonobese Diabetic Mice: Effects of Deleting the Adenovirus Death Protein 11.6K J. Virol., January 1, 2005; 79(1): 619 - 621. [Abstract] [Full Text] [PDF]